Baxter, Cerus Platelet Viral Inactivation System Enters Phase III Trial
This article was originally published in The Gray Sheet
Executive Summary
Baxter's Fenwal Division plans to manufacture, market and distribute a system intended to inactivate viruses, bacteria and other pathogens in platelet concentrations.